These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842 [TBL] [Abstract][Full Text] [Related]
8. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284 [TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
10. PET/CT With Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study. Çelen S; Gültekin A; Özlülerden Y; Mete A; Sağtaş E; Ufuk F; Yüksel D; Yağcı B; Zümrütbaş AE Urol Int; 2020; 104(9-10):684-691. PubMed ID: 32750695 [TBL] [Abstract][Full Text] [Related]
12. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC; Sundaram PS; Padma S Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer. Afaq A; Bomanji J Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121 [TBL] [Abstract][Full Text] [Related]
14. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Lin CY; Lee MT; Lin CL; Kao CH Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999 [TBL] [Abstract][Full Text] [Related]
15. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451 [TBL] [Abstract][Full Text] [Related]
17. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Giesel FL; Sterzing F; Schlemmer HP; Holland-Letz T; Mier W; Rius M; Afshar-Oromieh A; Kopka K; Debus J; Haberkorn U; Kratochwil C Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1400-6. PubMed ID: 26971788 [TBL] [Abstract][Full Text] [Related]
18. [The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer]. Mirzaei S; Knoll P; Zandieh S Wien Med Wochenschr; 2019 Feb; 169(1-2):12-14. PubMed ID: 30349972 [TBL] [Abstract][Full Text] [Related]
19. Berger I; Annabattula C; Lewis J; Shetty DV; Kam J; Maclean F; Arianayagam M; Canagasingham B; Ferguson R; Khadra M; Ko R; Winter M; Loh H; Varol C Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):204-211. PubMed ID: 29858591 [TBL] [Abstract][Full Text] [Related]